Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Sponsor: Kiminori Kimura, MD
Summary
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Official title: A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV/HCV Co-infection in the Setting of Hemophilia
Key Details
Gender
MALE
Age Range
18 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
7
Start Date
2026-10-01
Completion Date
2028-03-31
Last Updated
2026-10-05
Healthy Volunteers
No
Conditions
Interventions
Foscenvivint
Experimental:Foscenvivint Administered by intravenous (IV) infusion over 3-4 hours Arm Description:Foscenvivint 280 mg/m2, once a week for 24 weeks
Locations (4)
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
National Hospital Organization Sendai Medical Center
Sendai, Miyagi, Japan
National Hospital Organization Osaka National Hospital
Osaka, Osaka, Japan
Tokyo Metropolitan Komagome Hospital
Bunkyo-Ku, Tokyo, Japan